Literature DB >> 19773676

Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002-2008.

Hung Fu Tseng1, Ning Smith, Stephan Michael Marcy, Lina S Sy, Steven J Jacobsen.   

Abstract

BACKGROUND: Herpes zoster (HZ), or shingles, is caused by reactivation of latent varicella-zoster virus after a primary infection with either wild-type or vaccine-type varicella-zoster virus, the latter having been introduced in 1995 for children. Since then, few population-based data about the incidence of childhood HZ are available.
METHODS: We identified children aged < or = 12 years who were vaccinated with 1 dose of varicella vaccine between 2002 and 2008 in a prepaid health plan and followed them through their electronic health records for a diagnosis of HZ. The medical records of these children were reviewed. Persistent and chronic conditions for these children before HZ were identified.
RESULTS: There were 172,163 children vaccinated, with overall follow-up of 446,027 person-years (Incidence rate = 27.4 per 100,000 person-years, 95% confidence interval: 22.7-32.7). Children vaccinated after age 5 years had a higher but not statistically significant different rate than children vaccinated between 12 and 18 months (34.3 vs. 28.5 per 100,000 person-years). Among children vaccinated between 12 and 18 months, incidence rates gradually increased each year in the first 4 years after vaccination (P < 0.001). Among the HZ cases, there were 1 (0.7%) case of lymphoid leukemia, 1 (0.7%) case of drug abuse, 16 (11.1%) cases of asthma with 3 or more acute exacerbations, 12 (8.3%) cases of developmental disorders, and 3 (2.1%) cases of psychological or mental disorders.
CONCLUSIONS: These data demonstrate that diagnosed HZ is rare among children following varicella vaccine. Despite the small numbers, the roles of delayed vaccination, severe asthma, and development disorders warrant further investigation. In the future, analyses of HZ isolates will be needed to identify the virus strains causing reactivation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773676     DOI: 10.1097/INF.0b013e3181acf84f

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

1.  Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study.

Authors:  Kosuke Kawai; Barbara P Yawn; Peter Wollan; Rafael Harpaz
Journal:  Clin Infect Dis       Date:  2016-05-08       Impact factor: 9.079

Review 2.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

3.  Perspectives on vaccines against varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

4.  V1-distributed Herpes Zoster and Meningitis in a Two-year Old.

Authors:  Audrey S Wang; Tuyet Ann Nguyen; Andrew C Krakowski
Journal:  J Clin Aesthet Dermatol       Date:  2015-05

Review 5.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

6.  Increased risk of herpes zoster in children with asthma: a population-based case-control study.

Authors:  Bong-Seong Kim; Sonia Mehra; Barbara Yawn; Charles Grose; Robert Tarrell; Brian Lahr; Young J Juhn
Journal:  J Pediatr       Date:  2013-04-13       Impact factor: 4.406

Review 7.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

Review 8.  Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease?

Authors:  Young J Juhn
Journal:  J Allergy Clin Immunol       Date:  2014-08       Impact factor: 10.793

9.  Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study.

Authors:  Yuwei Sun; Eric Kim; Christina L Kong; Benjamin F Arnold; Travis C Porco; Nisha R Acharya
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

10.  In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency.

Authors:  Tomohiko Sadaoka; Daniel P Depledge; Labchan Rajbhandari; Arun Venkatesan; Judith Breuer; Jeffrey I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-12       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.